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Abstract
Chemotherapy-induced nausea and vomiting is one of the most concerning adverse drug effects
from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20–30% of
patients experience breakthrough nausea and vomiting secondary to chemotherapy. To assess the
variability of 5-hydroxytryptamine type 3 receptor antagonist efficacy caused by genetic variation,
a review of the available literature was conducted. From the literature, three sources of
pharmacogenomic variability were identified: polymorphisms associated with 5-
hydroxytryptamine type 3 receptor subunits, drug metabolism via cytochromes P450, and drug
transport in the body. Testing for receptor subunit polymorphisms is not applicable to a clinical
setting at this time; however, cytochrome P450 2D6 testing is FDA-approved and widely
accessible. Cytochrome P450 2D6 ultrarapid metabolizers and poor metabolizers displayed altered
antiemetic efficacy when compared with intermediate metabolizers and extensive metabolizers.
We postulate that testing for cytochrome P450 2D6 phenotypes may be the most accessible way to
provide individualized antiemetic therapy in the future.
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) is one of the most concerning and
debilitating adverse drug effects experienced by patients treated with cytotoxic
chemotherapy agents [1, 2]. Ineffective control of CINV can contribute to medication
noncompliance, patient distress, and decreased quality of life [3]. In order to stratify
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antiemetic treatment, chemotherapy agents have been divided into four groups on the basis
of risk of emesis without antiemetic treatment. These groups are high risk (90% or more
patients experience emesis), moderate risk (30–90% of patients experience emesis), low risk
(10–30% of patients experience emesis), and minimal risk (less than 10% of patients
experience emesis) [4–7]. The American Society of Clinical Oncology, the National
Comprehensive Cancer Network, the European Society of Medical Oncology, and the
Multinational Association of Supportive Care in Cancer guidelines primarily rely on three
classes of medications to treat CINV: 5-hydroxytryptamine (5HT; serotonin) type 3 (5HT3)
receptor antagonists (5HT3-RAs), neurokinin 1 receptor antagonists, and corticosteroids [4–
7].
The emetic pathway is activated through several different mechanisms. A major activator of
the chemoreceptor trigger zone is the release of 5HT from enterochromaffin cells in the gut
in response to the toxic environment and free radicals created by chemotherapy [1, 8–12].
Since the approval of ondansetron in 1991, 5HT3-RAs have played an important role in
treating acute CINV in highly and moderately emetogenic chemotherapy regimens [1, 9, 10,
12–14]. Even with appropriate antiemetic regimens, 20–30% of patients still experience
breakthrough CINV with chemotherapeutic agents categorized as having high and moderate
emetic risk [9, 10, 13, 15]. Variability in emetic control with 5HT3-RAs resulted in the
examination of the genetic variance in 5HT3 receptor subunits, genetic differences in
cytochrome P450 (CYP) metabolism of the various 5HT3-RAs, and polymorphisms
associated with drug transporters [2, 9, 13, 16–19]. This review serves to present the
available literature and to discern the impact of pharmacogenomics on 5HT3-RA efficacy in
patients receiving high- or moderate-emetic-risk chemotherapeutic agents. Table 1 provides
a summary of the referenced polymorphisms in drug target and transport genes. Ideally, this
review would help guide 5HT3-RA selection and improve antiemetic therapy outcomes.
Literature Search Strategy
A multitiered literature search strategy was employed in PubMed. Use of the following
medical subject headings (MeSH) terms provided few results: “nausea,” “serotonin,”
“receptors, serotonin, 5-ht3,” and “polymorphism, genetic.” A manual search of the review
articles during the background research produced 50 original research articles focused on
genetic polymorphisms in 5HT3 receptors. This method provided more CINV-related results
than searching with MeSH terms. To further refine the results, the following terms were
used to further exclude articles that involved 5HT3, but not CINV: “postoperative nausea
and vomiting,” “depression,” “paroxetine,” “irritable bowel syndrome” and “studies
conducted in non-human subjects.” Of those 50 articles, 12 were excluded owing to lack of
pharmacogenomic information or because they were published before identification of the
five subunits of 5HT3.
Genetic Polymorphisms Associated with Drug Target: 5HT3 Receptors
The 5HT3 receptor is a ligand-gated ion channel that is present in the hippocampus, area
postrema, and nucleus tractus solitarii [11, 20]. The five subunits that make up the pentamer
have been identified as 5HT3A, 5HT3B, 5HT3C, 5HT3D, and 5HT3E [13, 21–23]. The
subunits and the genes coding for them have become the target of studies of genetic
variation to explain suboptimal control with 5HT3-RAs [9, 10, 13, 15, 17, 24].
5HT3A
Kaiser et al. [17] sequenced the HTR3A gene (codes for the 5HT3A subunit) in 233 breast
cancer, lung cancer, non-Hodgkin’s lymphoma, Hodgkin’s disease, multiple myeloma, or
ovarian cancer patients being treated with highly emetogenic chemotherapies in an attempt
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to find a variant associated with CINV and explain the 20–30% variability in 5HT3-RA
efficacy. These patients received highly emetogenic chemotherapy regimens comprising
cyclophosphamide (mean dose 1,554 mg) or cisplatin (mean dose 88 mg), or moderately
emetic carboplatin (mean dose 424 mg). Tropisetron or ondansetron was administered
before chemotherapy, resulting in 23.7% of patients experiencing vomiting and 35.9%
experiencing nausea within the first 24 h [17]. Twenty-one polymorphisms were identified
(allelic frequencies ranging from 0.2 to 31.1%); however, no significant correlation to CINV
was established [17]. A nonsignificant trend of better CINV control was observed in M257I
heterozygotes than in homozygous patients [17]. Kaiser et al. [17] did not support the use of
M257I as a pharmacogenetic predictor of 5HT3-RA efficacy.
5HT3B
The HTR3B gene (codes for the 5HT3B subunit) must be coexpressed with HTR3A to
produce a functional 5HT3 receptor [21, 22, 25, 26]. The HTR3B gene also serves to modify
the function of subunit 3A by increasing single channel conductance in 3A/3B heteromeric
receptors, making the receptor more responsive to 5HT [16, 25, 26]. Because of its role in
the overall function of the 5HT3 receptor, Tremblay et al. [16] hypothesized that
polymorphisms in the HTR3B gene might have an impact on acute CINV and 5HT3-RA
efficacy. Tremblay et al. sequenced DNA from venous blood samples from the same
patients examined by Kaiser et al. The frequencies of the variations highlighted two major
polymorphisms: -100_-120delAAG promoter region deletion in the start codon of the
5HT3B gene (frequency 0.1), linked with a T129S variant (frequency 0.3) in exon 5 [16,
27]. In patients who experienced CINV during both observational periods (0–4 h, 5–24 h),
those homozygous for the -100_-120delAAG deletion had a much higher frequency of
vomiting than any other patient [16, 17, 27]. After adjustment for Bonferroni correction, the
association of -100_-120delAAG deletion and vomiting was deemed not statistically
significant [16].
On further examination, multivariate analysis affirmed that the poor CINV control
associated with the deletion was not due to the level of chemotherapeutic emetic risk,
coadministered medications, or CYP2D6 status [16]. Tremblay et al. suggested that patients
who were homozygous for the HTR3B gene -100_-120delAAG and were CYP2D6
intermediate metabolizers (IMs) experienced greater CINV incidence than patients with
more than one active CYP2D6 gene expressed (extensive metabolizers, EMs, or ultrarapid
metabolizers, UMs) [16]. An additive genetic effect was noted in terms of intensity of CINV
among wild-type, heterozygous, and homozygous HTR3B variant patients [16]. Meineke et
al. [27] genotyped 59 healthy patients for the -100_-120delAAG polymorphism to determine
the effect of the polymorphism on the HTR3B promoter activity. The three-base-pair
deletion resulted in a 25–40% increase in promoter activity in vitro, which Meineke et al.
[27] concluded would alter the severity of CINV.
Perwitasari et al. [28] conducted a study to compare the frequency of the 5HT3B receptor
-100_-120delAAG deletion and 18792A>G (rs4938058) and 46698G>A (rs7943062)
polymorphisms in 165 Indonesian cancer patients and 188 healthy Caucasians [16, 27].
Significant differences in the AAGAG and AAGGG haplotypes of the 5HT3B gene between
Indonesians and Caucasians were observed (P < 0.05) [28]. The haplotype frequency in
Indonesians and Caucasians was 19% and 34%, respectively, which may explain the
interethnic differences in response to 5HT3-RAs [28]. Perwitasari et al. [28] reported that the
allele frequencies of the SNPs seen in the Caucasians in the study of Tremblay et al. [16]
were closely comparable, implying that disease state has no effect on frequency.
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5HT3C, 5HT3D, and 5HT3E
The discoveries of the HTR3C, HTR3D, and HTR3E genes in 2003 have added to the
possible explanations for poor CINV control with 5HT3-RAs [29]. Similar to HTR3B,
HTR3C, HTR3D, and HTR3E also require coexpression with HTR3A in order to form
functional receptors [30]. Study of the 5HT3D subunit has revealed only one SNP
nonsignificantly associated with a higher incidence of antiemetic therapy failure in
nonresponders [31]. The 5HT3E subunit has not yet been studied in CINV.
Fasching et al. [18] assessed 5HT3C receptor gene polymorphisms and the incidence of
CINV after ondansetron and dexamethasone therapy in 110 German breast cancer patients
treated with anthracyclines. The study identified one SNP, K163N (rs6766410), which was
associated with an increased incidence of poorly controlled CINV in 50% of C/C
homozygous patients (P = 0.009) as compared with 22% of A/A (wild type) or A/C patients
[18].
A study of 5HT3C receptor polymorphisms and failure of 5HT3-RAs in 70 Australian cancer
patients treated with chemotherapy and dolasetron or tropisetron did not replicate these
findings [24]. The variant rs6766410 and two other identified variants were not statistically
significant for increased incidence of poorly controlled CINV (P = 0.266–1.000) [18, 24].
The study concluded that none of the polymorphisms seen in the 5HT3C receptor gene were
predictive of 5HT3-RA response [24]. Further research, with larger study populations, will
be required to validate the findings associated with rs6766410.
The clinical implications of the genetic variability within the individual subunits of the
5HT3 receptor remain to be seen. The most variability occurred with the 3B subunit; in
which, the -100_-120delAAG deletion has the most potential to explain variation due to the
receptor structure. Use of this variability to predict efficacy of CINV control is limited
owing to the need for validation across larger and more diverse populations. The 3C, 3D,
and 3E subunits have failed to produce any statistically significant variations that could
impact clinical decision making.
Genetic Polymorphisms in Drug-Metabolizing Enzymes: The CYPs
Affecting 5HT3-RA
The CYP family of enzymes is collectively responsible for approximately 75% of drug
metabolism in the human body [32]. Of the drugs metabolized by CYPs, approximately 85–
95% of them are metabolized by seven specific CYPs: CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, CYP3A4, and CYP3A5 [2, 32]. The 5HT3-RAs are not exempt from
this, and although they have a conserved mechanism of action, their CYP profiles differ (see
Table 2). CYP2D6 is notable as a major metabolic pathway for several of the 5HT3-RAs,
followed closely by CYP3A. Over 75 allelic variants have been identified for CYP2D6
alone, which creates the potential for a multitude of adverse drug reactions and may alter the
efficacy of medications that rely on the enzyme as a major metabolic pathway [33].
Cytochrome P450 2D6
CYP2D6 is well known for its involvement in many drug therapies (e.g., tamoxifen,
antipsychotics, tricyclic antidepressants, and selective serotonin reuptake inhibitors). The
5HT3-RAs ondansetron, palonosetron, ramosetron, tropisetron, and dolasetron rely on
CYP2D6 metabolism in differing degrees. Granisetron is the only 5HT3-RA that does not
rely on CYP2D6. The identification of a patient’s CYP2D6 phenotype may help guide
clinician choices in antiemetic therapy. There are four distinct phenotypes of the CYP2D6
enzyme: poor metabolizers (PMs), IMs, EMs, and UMs. Ethnic variability of CYP2D6
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phenotypes exists, making polymorphisms harder to predict [33]. The EM phenotype, a
“normal patient” who has two functioning alleles, is the commonest across all ethnicities
[33, 34]. PMs compose roughly 5–10% of Caucasian patients and are the result of
inheritance of two defective genes [34–37]. It is estimated that PMs compose roughly 7% of
the Caucasian population and up to 19% of South Africans [33]. The incidence of PMs is
virtually undetected in Japanese and Chinese populations (0–2%) and is on average less than
5% in Turkish, Croatian, Asian, African, and Hispanic populations [33]. There is not much
evidence to support dose reductions in PM patients, as adverse drug events are typically
mild (e.g., headache, fatigue, and constipation).
Attempts have been made to convert a PM to an EM via enzyme induction as a way to
decrease the incidence of adverse effects associated with supratherapeutic concentrations;
however, CYP2D6 does not react to enzyme induction [35, 38, 39]. Although a PM has low
CYP2D6 expression overall, the enzymes that are available function at a high capacity when
exposed to supratherapeutic concentrations of CYP2D6-specific HT3-RAs.
The weakest control of CINV with 5HT3-RAs is seen in the UM population [9, 34, 40].
Kaiser et al. [35] reported that four UM patients (1.5%) had a significantly higher mean
number of vomiting episodes compared with all the IMs, PMs, and EMs receiving initial
doses of cyclophosphamide, cisplatin, or carboplatin, 2.3 ± 2.5 vs 0.2 ± 1.0 (P <0.001)
episodes of vomiting, respectively. In addition, UM patients experienced severer nausea
than other patients despite use of ondansetron or tropisetron [35]. These patients have at
least one active allele and one or two duplication alleles, causing the rapid metabolism of
medications and loss of efficacy [35, 37]. The frequency in these patients differs widely
among ethnic groups. UMs are present in less than 5% of Caucasian patients (e.g., 4.3% in
America, 0.8% in Germany), with the exception of Turkish (8.7%) and Spanish (10%)
patients [33, 35]. The frequency differs widely in African and Asian populations: 4.9% in
African-Americans, 29% in Ethiopians, 0.9% in Chinese, and 21% in Saudi Arabians [33].
Several options remain for suspected UM patients with poor CINV control. Granisetron is
the only 5HT3-RA that does not involve CYP2D6 in its metabolism; thus, it might be the
most reasonable option in a suspected UM patient [41]. If switching 5HT3-RAs does not
have an effect on the poorly controlled CINV, the major CINV guidelines support the
addition of a neurokinin 1 receptor antagonist [4–7].
It is also important to note the large variability in metabolic activity of IM patients. For
example, IM patients with high enzymatic function are very similar to EMs, and IMs with
low enzymatic function are hard to discern from PMs. IM patients with true IM behavior
would be hard to identify without a CYP2D6 activity probe such as dextromethorphan.
Bernard et al. [33] reported only three frequencies of IMs with diminished activity: 1–2% in
Caucasian populations, 51% in Asians (excluding Saudi Arabians), and 3–9% in Saudi
Arabians. If breakthrough or refractory CINV occurs in these individuals, successful
treatment is more difficult as the phenotype is hard to predict without formal testing.
Cytochrome P450 3A4
CYP3A4 is perhaps the most well known drug-metabolizing enzyme in the human body,
with approximately 40–60% of drug metabolism being performed by CYP3A4 [34, 36].
Individual variations in enzymatic activity can be traced back to genetics; however, no
incontrovertible link has been established as the CYP3A4 gene is highly conserved [34].
Research has been directed at the flanking regions of the CYP3A4 gene, and several
mutations have been identified. These mutations may have a potential impact on granisetron,
the only 5HT3-RA that primarily relies on the CYP3A4 pathway for metabolism. Despite
successful in vitro studies, CYP3A4*1B has failed to produce conclusive in vivo evidence
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[42]. Research has also identified several other variant alleles, each with no in vivo effects
and allele frequencies of 5% or less: CYP3A4*2, CYP3A4*10, CYP3A4*14, CYP3A4*15,
and CYP3A4*16 [42].
Hassan and Yusoff [43] conducted a longitudinal prospective observational study among
158 breast cancer patients from Penang, Malaysia, in which they analyzed genetic
polymorphisms and their effect on CINV control with granisetron. Each patient was treated
with granisetron and dexamethasone, and was followed up within 3–5 days after
chemotherapy [43]. The incidence of acute CINV in the Indian population was much lower
than the Chinese and Malay populations [43]. This difference was attributed to the absence
of CYP3A4*2, CYP3A4*5, CYP3A4*6, and CYP3A4*10 alleles in the Indian population,
thus producing higher granisetron concentrations [43]. The CYP3A4*18 mutation that
causes decreased enzymatic activity is common among Malay individuals [43]. However,
Chinese patients are unlikely to carry mutations (including *4 and *5) that cause decreased
activity [43].
The differing frequencies of the CYP2D6 phenotypes and CYP3A4 activity are important to
keep in mind as populations increase, health care expands, and genetic testing becomes more
accessible. According to projections made after the 2010 US census, the Hispanic
population in the USA is expected to triple by 2050 and the Asian population is expected to
increase by 4.1%, accounting for 40.6 million US citizens [44]. The variation in CYP2D6
activity currently has the potential for the largest impact in clinical decisions for CINV
control. CYP2D6 genotype testing has already been used in different disease states to help
individualize patient therapy. Codeine, for example, is commonly known as a prodrug that is
dependent on CYP2D6 activity for conversion into morphine [45]. The four phenotypes of
CYP2D6 can affect prodrug conversion and thus pain control. For example, UMs are at a
significantly increased risk of developing opioid-induced toxicity, whereas PMs may not
achieve appropriate therapeutic pain relief [45].
Genetic Variation in Drug Transport: 5HT3-RAs
When attempting to explain variability in efficacy of 5HT3-RAs, it is important to consider
if enough of the administered dose is making it to the target receptor, and if the medication
is being removed from the target. The ATP-binding cassette subfamily B member 1
(ABCB1) transporter functions as an efflux pump for a variety of substances, including the
5HT3-RAs ondansetron and ramosetron [46, 47]. This is of special significance to antiemetic
activity, as ABCB1 is thought to be an active part of the blood–brain barrier. The
membrane-associated protein ABCB1 is also known as p-glycoprotein, a multi-drug-
resistant protein 1 [46, 47]. The ABCB1 3435C>T variant is correlated with significantly
reduced expression of ABCB1, causing increasing concentrations of medications that
require ABCB1 for drug efflux [46, 47].
Babaoglu et al. [46] tested the hypothesis that patients with the ABCB1 3435T allele would
have superior CINV protection in 216 cancer patients in Turkey and Germany taking
granisetron, ondansetron, or tropisetron for moderate to highly emetic chemotherapy.
Overall, 40% of patients experienced poor control of CINV in the first 24 h after receiving
chemotherapy [46]. Patients who were treated with granisetron and were homozygous for
the 3435C>T variation experienced a significantly higher rate of CINV control than patients
who were heterozygous or homozygous for the C allele: 92.9% in TT patients versus 47.6%
in CT patients (P = 0.009) and 56.1% in CC patients (P = 0.02) treated with granisetron [46].
The presence of the 3435T variation did not significantly improve CINV control in the
ondansetron group, and had no effect in the tropisetron group [46]. Babaoglu et al. [46]
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concluded that the ABCB1 variant 3435C>T could explain some pharmacologic variability
in efficacy of the 5HT3-RAs.
In addition to ABCB1, the 5HT3-RAs can also be affected by polymorphisms in the organic
cation transporters (OCTs), which are responsible for organic cation uptake in the liver [40].
OCT1 is the commonest form, and has several polymorphisms associated with reduced
activity: R61C, C88R, G410S, and M420del [40]. Tzvetkov et al. [40] examined the impact
of OCT1 and CYP2D6 polymorphisms on 5HT3-RA efficacy in 253 German cancer patients
receiving ondansetron or tropisetron for treatment of CINV. Ondansetron concentrations
were determined to be independent of OCT1, whereas tropisetron concentrations correlated
with OCT1 expression [40]. Genotyping showed that 12% of patients were homozygous for
reduced-activity alleles, 38% were heterozygous, and 50% were homozygous for the active
alleles [40]. The patients with reduced activity (one or more reduced-activity allele) of
OCT1 had increased concentrations of tropisetron, causing greater CINV control than
patients homozygous for regular OCT1 activity [40]. Tzvetkov et al. concluded that in
addition to CYP2D6 variability, OCT1 polymorphisms could potentially contribute to
individual variability in 5HT3-RA efficacy. However, the ABCB1 and OCT1 study results
do not currently impact clinical decision making owing to their limited findings and the need
for further study.
Application of Pharmacogenomics to Personalized CINV Medication
Regimens
This review has covered variations in drug target, metabolism, and transport genes, in which
pharmacogenomics may impact 5HT3-RA efficacy in treating CINV; however, providing
individualized patient care based on genetics is not always feasible. Several barriers exist in
the translation of pharmacogenomic information to health care providers and clinical
practice.
One major issue involves small study populations. For example, the study population never
exceeded 300 patients for all the studies noted. These small study populations make
detecting an actual polymorphism difficult because of the low (less than 0.1) allele
frequencies of a variant, such as the -100_102delAAG variant, which was only expressed in
1.2% of the study population [16]. After a Bonferroni analysis has been performed, the p
values of the SNPs were often not statistically significant. Increasing study population sizes
will make detecting low-frequency variants easier, and also increase the study’s power.
Translation to the clinical setting will also be hampered by the need for large study
populations, therefore increasing costs and resource demands.
In addition to small populations, studies are typically conducted in isolated patient
populations (e.g., breast cancer patients admitted to ward C11 or ward C19 in Penang
Hospital) [43]. These isolated groups further contribute to difficulties in detecting actual
allele variants. Although studies are easier to conduct with small populations, the small size
prevents the results from being extrapolated to a larger population (e.g., Malaysians).
Increasing study population sizes seems simple in theory, but not every hospital, clinic, or
university has the ability to conduct “in-house” genetic testing. Although, there are several
clinical laboratory networks available for pharmacogenomic testing in the USA (e.g.,
LabCorp, Quest Diagnostics), developing nations often lack these facilities and may only
have newly formed pharmacogenomic programs. The root cause of this lack of resources is
often a lack of funding, as equipment and personnel needed to collect and interpret
pharmacogenomic data can be prohibitively expensive. As a result, increasing study
population sizes may be impossible if there is limited access to patient genomic information.
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Another major issue with extrapolating the pharmacogenomic data reviewed here is that the
only validated pharmacogenomic tests available are for CYP2D6 and CYP3A4. No
clinically available test currently exists for 5HT3 receptors, ABCB1, or OCT1, all of which
contribute to patient variability. Accumulation of sufficient clinical evidence to validate a
test’s efficacy and predictive powers often takes many years. Additionally, it may take
several years before the cost of the test becomes low enough for widespread clinical use.
The variants found in the studies were determined by laboratory methods that would be
impractical for an individual patient basis.
Testing for CYP2D6 is becoming more convenient in the USA and other developed nations,
and is commoner than ever before, but the cost to the patient will always be a barrier.
Insurance companies are not always willing to pay for genetic testing, especially for a non-
life-threatening condition such as CINV. Bernard et al. [33] reported that in a psychiatric
setting, CYP2D6 PM and UM patients cost $4,000 more per year to treat than IM or EM
patients. One-time-only CYP2D6 function testing typically costs less than $500, and the
results pertain to several other drugs relevant to cancer patients, e.g., tamoxifen, codeine,
and antidepressants. However, the cost of a single day in hospital because of drug toxicities
quickly exceeds the cost of most commercially available genetic tests. A prime example is
early CYP2D6 genotyping of acute lymphoblastic leukemia patients at St. Jude Children’s
Hospital [45]. These patients will likely use codeine-containing analgesics at some point
during their treatment, so identifying PMs and UMs before giving an ineffective or
potentially toxic dose is extremely cost-effective [45]. The genotyping results could be
directly applied to help guide clinical decisions regarding CINV control with 5HT3-RAs.
When compared with the ease and availability of CYP2D6 testing, CYP3A4 erythromycin
breath testing (EBT) is a less appealing option. Erythromycin is radiolabeled with 14C,
which is N-demethylated in the body and converted to 14CO2 and then exhaled [48]. There
is a lot of conflicting information about the predictive ability of EBT in many patients;
however, Rivory [48] reported that EBT was predictive in the clearance of erythromycin in
16 cancer patients, but further study is required. The pricing and availability of EBT is not
readily available, and considering that there are four 5HT3-RAs that do not rely on CYP3A4
for primary metabolism, EBT is not an attractive option.
Enhancing our current antiemetic prophylaxis guidelines involves incorporating CYP2D6
phenotypic testing into our laboratory repertoire. Figure 1 depicts a proposed, enhanced
treatment algorithm in which each patient who is designated to receive chemotherapy
requiring 5HT3-RAs (high and moderate emetic risk) is phenotyped before treatment.
Another proposed method (not pictured) is to perform genetic testing on every patient
receiving a chemotherapy agent with high, moderate, or low emetic risk. This method would
not be cost-effective; however, it would provide useful information, as cancer patients often
require analgesics and antidepressants which rely on CYP2D6. Another proposed algorithm
includes testing individuals who have experienced breakthrough or refractory CINV, in an
attempt to isolate UMs. However, the way we adjust our algorithms, CYP2D6 testing is an
essential part of providing patients with personalized medical care.
Conclusions
Although many polymorphisms exist that might explain patient variability in 5HT3-RA
efficacy for acute CINV, the only clinically actionable data points are CYP2D6 and
CYP3A4 polymorphisms. We examined several 5HT3 receptor subunit polymorphisms;
however, most of them could not be directly associated with poor CINV control. More
research is needed to establish statistical significance of the 3B -100_-120delAAG variant as
a marker of reduced 5HT3 receptor function. The recently discovered 3C and 3D subunits
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have also been implicated, but the reported variants require validation in larger patient
populations and in different ethnicities. Currently, 5HT3 receptor subunit E and its
implications on CINV have not be elucidated. Aside from the 5HT3 receptor functionality
and 5HT3-RA metabolism, drug transport is the remaining factor. Variations resulting in
altered activity of ABCB1 and OCT1 may contribute to the heterogeneity in antiemetic
response; however, validation studies and consistent tests for predicted activity are major
barriers. Currently in clinical practice, CYP2D6 genetic testing is readily available and may
be used to guide future 5HT3-RA regimen choices because of its consistent clinical data,
relatively low cost, and high patient benefit. As genetic testing becomes more widely
accepted and new medications become more patient specific, pharmacogenomics will be an
additional tool to help individualize 5HT3-RA therapy to prevent and treat CINV.
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An individualized antiemetic treatment algorithm using the cytochrome P450 (CYP) 2D6
genotype. An example of an enhanced drug treatment algorithm designed for individualized
emetic prophylaxis for patients requiring 5-hydroxytryptamine type 3 receptor antagonists
(5HT3-RAs). This algorithm suggests performing CYP2D6 genotyping on patients after
their diagnosis and the decision to use chemotherapy agents that require 5HT3-RAs. The
timing of the genotyping would differ on the basis of institutional ability to do in-house
genotyping or the use of a clinical laboratory network. Variations on this algorithm could
also include genotyping at diagnosis. ASCO American Society of Clinical Oncology, EM
extensive metabolizer, ESMO European Society of Medical Oncology, IM intermediate
metabolizer, MASCC Multinational Association of Supportive Care in Cancer, NCCN
National Comprehensive Cancer Network, NK1-RA neurokinin 1 receptor antagonist, PM
poor metabolizer, UM ultrarapid metabolizer,
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Table 1
Referenced polymorphisms




5HT3A receptor (11q23.1) NC_000011.9 (113845797..113861035) A33T Not associated Krzywkowski
et al. [22]




R344H Not associated Krzywkowski
et al. [22]
P391R Not associated Krzywkowski
et al. [22]
S253N Not associated Krzywkowski
et al. [22]




T129S (rs1176744) Not associated
18792A>G (rs4938058) Not associated Perwitasari et
al. [28]
46698G>A (rs7943062) Not associated Perwitasari et
al. [28]
5HT3C receptor (3q27.1) NC_000003.11 (183770835..183778461) K163N (rs6766410) Not associated Fasching et
al. [18], Ward
et al. [24]
5HT3D receptor (3q27.1) NC_000003.11 (183749332..183757157) G36A (rs6443930) Not associated Hammer et
al. [31]
ABCB1 (7q21.12) NC_000007.13 (87133179..87342639, complement) 3435C>T (rs1045642) Possibly associated Ishikawa et
al. [47]








5HT3 5-hydroxytryptamine type 3, ABCB1 ATP-binding cassette subfamily B member 1, OCT1 organic cation transporter 1
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Table 2
Cytochrome P450 (CYP) profiles of available 5HT3 rector antagonists [2, 43, 49–54]
5HT3-RA Major P450(s) Minor P450(s) Notable availability
Dolasetron (a prodrug, must be
converted to reduced dolasetron by
carbonyl reductase)
CYP2D6 CYP3A4 Not available in the USA
Granisetron CYP3A
Ondansetron No dominant P450 CYP1A1, CYP1A2,
CYP2D6, CYP2E1, CYP3A4
Palonosetron CYP2D6 CYP3A, CYP1A2
Ramosetron CYP1A2, CYP2D6 Only available in Japan and Southeast Asia
Tropisetron CYP2D6 Not available in the USA
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